Xeris Biopharma Q2 revenue up 49% to $71.5M; Recorlev +136%; raises FY guidance to $280-290M

Xeris Biopharma Holdings, Inc.

2025-Q2 EPS reported -$0.07 revenue$131,658,000

Total revenue $71.5M (+49% YoY); net loss narrowed to $1.9M ($0.01/sh) from $15M ($0.10/sh).
Recorlev net revenue $31.4M (+136%) driven by 122% increase in average patients on therapy.
Gvoke revenue $23.5M (+17%); Keveyis $11.5M (-13%) on reduced shipments.
Adjusted EBITDA improved to $12.5M vs -$0.4M in Q2 2024.
Raised FY 2025 revenue guidance to $280-290M from $260-275M; long-term target $750M by 2030.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.